PPT1 and hepatocellular carcinoma: Inhibition of PPT1 augments anti-PD-1 immunotherapy by elevating major histocompatibility complex (MHC)-I expression on hepatocellular carcinoma cell surfaces and influences immunity via the recolonization and activation of cytotoxic CD8+ lymphocytes (141).